These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9538519)

  • 1. Superposition of three-dimensional chemical structures allowing for conformational flexibility by a hybrid method.
    Handschuh S; Wagener M; Gasteiger J
    J Chem Inf Comput Sci; 1998; 38(2):220-32. PubMed ID: 9538519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The conformation and activity relationship of fused analogs of DuP753.
    Yoo SE; Shin YA; Lee SH; Kim NJ
    Bioorg Med Chem; 1995 Mar; 3(3):289-95. PubMed ID: 7606390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
    Krovat EM; Langer T
    J Med Chem; 2003 Feb; 46(5):716-26. PubMed ID: 12593652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 3D QSAR CoMFA study of non-peptide angiotensin II receptor antagonists.
    Belvisi L; Bravi G; Catalano G; Mabilia M; Salimbeni A; Scolastico C
    J Comput Aided Mol Des; 1996 Dec; 10(6):567-82. PubMed ID: 9007690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of nonpeptide angiotensin II receptor antagonists featuring acyclic imidazole-mimicking structural units.
    Angiolini M; Belvisi L; Poma D; Salimbeni A; Sciammetta N; Scolastico C
    Bioorg Med Chem; 1998 Nov; 6(11):2013-27. PubMed ID: 9881093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure elucidation and conformational properties of eprosartan, a non peptide angiotensin II AT1 antagonist.
    Zoumpoulakis P; Grdadolnik SG; Matsoukas J; Mavromoustakos T
    J Pharm Biomed Anal; 2002 Apr; 28(1):125-35. PubMed ID: 11861115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor antagonism: losartan - sites and mechanisms of action.
    Triggle DJ
    Clin Ther; 1995; 17(6):1005-30. PubMed ID: 8750395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular shape comparison of angiotensin II receptor antagonists.
    Masek BB; Merchant A; Matthew JB
    J Med Chem; 1993 Apr; 36(9):1230-8. PubMed ID: 8487259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of KR-30988, a novel non-peptide AT1 receptor antagonist, in rat, rabbit and dog.
    Lee BH; Lee SH; Jung YS; Seo HW; Yoo SE; Shin HS
    J Pharm Pharmacol; 1999 Oct; 51(10):1191-200. PubMed ID: 10579691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor.
    Prendergast K; Adams K; Greenlee WJ; Nachbar RB; Patchett AA; Underwood DJ
    J Comput Aided Mol Des; 1994 Oct; 8(5):491-512. PubMed ID: 7876897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.
    Polevaya L; Mavromoustakos T; Zoumboulakis P; Golic Grdadolnik S; Roumelioti P; Giatas N; Mutule I; Keivish T; Vlahakos DV; Iliodromitis EK; Kremastinos DT; Matsoukas J
    Bioorg Med Chem; 2001 Jun; 9(6):1639-47. PubMed ID: 11408184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shared determinants of receptor binding for subtype selective, and dual endothelin-angiotensin antagonists on the AT1 angiotensin II receptor.
    Dascal D; Nirula V; Lawus K; Yoo SE; Walsh TF; Sandberg K
    FEBS Lett; 1998 Feb; 423(1):15-8. PubMed ID: 9506833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries.
    Li Q; Pfaffendorf M; van Zwieten PA
    Fundam Clin Pharmacol; 2001 Apr; 15(2):143-50. PubMed ID: 11468024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
    Lee SH; Jung YS; Lee BH; Yun SI; Yoo SE; Shin HS
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):367-74. PubMed ID: 10069670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of losartan (DuP 753)-induced angiotensin II receptor antagonism by PD123177 in rats.
    Wong PC; Christ DD; Timmermans PB
    Eur J Pharmacol; 1992 Sep; 220(2-3):267-70. PubMed ID: 1425998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for the chemical development of angiotensin II receptor antagonists.
    Wexler RR; Carini DJ; Duncia JV; Johnson AL; Wells GJ; Chiu AT; Wong PC; Timmermans PB
    Am J Hypertens; 1992 Dec; 5(12 Pt 2):209S-220S. PubMed ID: 1290616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Losartan: the first angiotensin receptor antagonist in clinical use.
    Beevers DG
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S1. PubMed ID: 8583475
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunological reactivity of angiotensin II receptor antagonists: possible implications for receptor binding sites.
    Bensoussan M; Mitchell T; Reilly T; Timmermans PB; Verroust PJ; Ronco PM
    Eur J Pharmacol; 1993 Oct; 247(2):169-75. PubMed ID: 8282006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension.
    Hashimoto Y; Ohashi R; Minami K; Narita H
    Jpn J Pharmacol; 1999 Sep; 81(1):63-72. PubMed ID: 10580372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
    Montón M; Jiménez A; Núñez A; López-Blaya A; Farré J; Gómez J; Zalba LR; Sánchez de Miguel L; Casado S; López-Farré A
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.